Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexue Tongbi Powder is a Traditional Chinese Medicine (TCM) herbal formulation developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is specifically designed as an external adjuvant therapy for patients with colorectal cancer experiencing oxaliplatin-induced peripheral neuropathy (OIPN). The formulation is typically administered as a topical soak (hand or foot bath). According to TCM principles, the powder functions to harmonize the blood, resolve blood stasis, and unblock the collaterals, addressing the underlying pathogenesis of chemotherapy-induced nerve damage. Clinical research indicates that it may alleviate sensory symptoms such as numbness, tingling, and cold-induced paresthesia by improving local microcirculation and potentially exerting anti-inflammatory effects on peripheral nerve endings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hexue Tongbi Powder.